Brixadi extended-release subcutaneous injection receives FDA approval for moderate to severe opioid use disorder – Braeburn
Braeburn announces that the FDA has approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (CIII), a new weekly and monthly medication for moderate to severe opioid use disorder… read more.
